Roberta Duncan

Vice President, mRNA Program
  • CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines providing lifesaving products and vaccines to patients and public health in more than 100 countries.
  • CSL’s commitment to population protection is evidenced through an innovative vaccines pipeline, which includes technologies such as self-amplifying mRNA.
  • CSL’s self-amplifying mRNA technology serves as one of the company’s strategic scientific platforms.
  • CSL’s vaccine business, CSL Seqirus, focuses on developing differentiated vaccines utilizing innovative technologies, including the self-amplifying messenger RNA (sa-mRNA) platform, protecting against respiratory viruses, influenza, COVID-19, and seasonal and pandemic potential viruses.